Chromedx Announces Collaborative Project with McMaster University
Toronto, Ontario--(Newsfile Corp. - November 17, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that it has reached an agreement with McMaster University on a collaborative project. The collaborative Project led by ChroMedX Technical Advisory Board member Dr. Cynthia Balion will provide the necessary laboratory space for ChroMedX to handle and treat blood samples in the...
2014-11-17 3:30 AM EST
ChroMedX Engages Dr. Hai Shiene Chen as Asia Business Development Advisor
Toronto, Ontario--(Newsfile Corp. - November 11, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the “Company”), is pleased to announce the engagement of Dr. Hai Shiene Chen of ACGT Corporation of Toronto, Ontario to assist the Company in the international commercialization of its innovative point of care and in-vitro diagnostics technologies in the Asian market. Dr. Chen will assist the Company by pursuing development/commercialization opportunities for the Company’s blood...
2014-11-11 3:30 AM EST
ChroMedX Announces Operations Update and Advisory Board Appointment
Toronto, Ontario--(Newsfile Corp. - October 28, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide a HemoPalm development update and announce Dr. Cynthia Balion as the first appointment to the Company's Technical Advisory Board. Dr. Wayne Maddever, P.Eng., Chief Executive Officer of ChroMedX Corp. is pleased to provide the following update on the Company's HemoPalm...
2014-10-28 1:30 AM EDT
ChroMedX Announces HemoPalm Trademark and Intellectual Property Update
Toronto, Ontario--(Newsfile Corp. - October 23, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the trademark for the Company's patented HemoPalm technology has been allowed by the United States Patent and Trademark Office and will be officially registered when the HemoPalm is released commercially. The HemoPalm technology is currently covered by two issued and one...
2014-10-23 3:30 AM EDT
ChroMedX Corp Announces Grant of Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (the "Company") announces that it has granted an aggregate of 600,000 options to purchase common shares of the Company exercisable at a price of $0.18 per share and expiring on October 6, 2017, to certain consultants of the Company. The consultants concerned bring expertise to the Company in several key areas. These include the electrochemical and spectroscopic technologies incorporated in the...
2014-10-06 3:26 PM EDT
ChroMedX Corp. Information to be Available through S&P Capital IQ Corporation Records Program
Toronto, Ontario--(Newsfile Corp. - September 26, 2014) - ChroMedX Corp. (OTC: MNLIF) (CSE: CHX) announced today that its company information would be made available via S&P Capital IQ Corporation Records Listing Program. As part of the program, a full description of ChroMedX Corp. will be published in the Daily News Section of Standard & Poors's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation...
2014-09-26 10:55 AM EDT
ChroMedX Corp Closes Oversubscribed Private Placement
Toronto, Ontario--(Newsfile Corp. - September 22, 2014) - ChroMedX Corp. (CSE: CHX) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of CDN$614,500 through the issuance of 6,145,000 units (each a "Unit") at a price of CDN$0.10 per Unit. As a result of the Offering being oversubscribed, the board of directors increased the private placement offering from CDN$500,000 to CDN$650,000. Each Unit...
2014-09-22 4:23 PM EDT
Monarch Energy Changes Its Name to ChroMedX Corp.
Toronto, Ontario--(Newsfile Corp. - September 17, 2014) - Monarch Energy Limited (CSE: CHX) (the "Company") is pleased to announce that pursuant to articles of continuance dated September 8, 2014, Monarch Energy Limited has continued from the province of British Columbia to the Province of Ontario and has changed its name to "ChroMedX Corp." The common shares of the Company will begin trading under its new name on September 18, 2014 under the current trading symbol "CHX". About ChroMedX...
2014-09-17 3:19 PM EDT
Monarch Energy Announces Results of Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - August 29, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") announces that the shareholders of the Company have approved, at the Annual General and Special Meeting held on August 29, 2014, all of the items set forth in the Company's management information circular dated July 30, 2014 and mailed to the shareholders, including: (i) change of the Company's name to ChroMedX Corp.; (ii) continuance of the Company from British...
2014-08-29 1:28 PM EDT
Monarch Energy as ChroMedX Ltd. Engages ALine Inc. for Development of HemoPalm Cartridges and Handheld Analyzer
Toronto, Ontario--(Newsfile Corp. - July 29, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") is pleased to announce that its wholly-owned subsidiary ChroMedX Ltd. has engaged ALine Inc. of Rancho Dominguez, CA as its primary contractor for the development of the Company's HemoPalm cartridge and analyzer technology. The goal is to complete construction of the prototype cartridge and analyzer to demonstrate functionality of the system by the first quarter of...
2014-07-29 11:10 AM EDT
Monarch Energy Commences Business in the Medical Diagnostics and Research Field
Toronto, Ontario--(Newsfile Corp. - July 11, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") is pleased to announce that the Company has commenced business in the in vitro medical diagnostics and point-of-care testing field under its wholly owned subsidiary ChroMedX Ltd. Technologies The Company will now focus its efforts on commercializing technologies, protected by issued and pending patents developed by Dr. James Samsoondar, the Company's Chief Science...
2014-07-11 2:49 PM EDT
Monarch Energy Announces Appointment of a Director and Grants Options
Toronto, Ontario--(Newsfile Corp. - July 9, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") announces that it has granted an aggregate of 2,950,000 options to purchase common shares of the Company exercisable at a price of $0.10 per share and expiring on July 9, 2019, to certain directors, officers and consultants of the Company. The common shares issuable upon exercise of the options are subject to a four-month hold period from the original date of grant....
2014-07-09 5:16 PM EDT
Monarch Energy Enters into Share Exchange Agreement with ChroMedX Ltd.
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2013) - Monarch Energy Limited (TSXV: MNL) ("Monarch" or the "Company") is pleased to announce that is has entered into a share exchange agreement as of December 20, 2013 with ChroMedX Ltd. ("ChroMedX") and ChroMedX Inc. pursuant to which the Company has agreed to acquire from the ChroMedX shareholders all of the issued and outstanding shares of ChroMedX in exchange for an equal number of common shares in the capital of the Company...
2013-12-20 2:15 PM EST
IIROC Trade Halt - Monarch Energy Limited
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2013) - The following issues have been halted by IIROC: Company: Monarch Energy Limit
2013-12-20 11:26 AM EST